Literature DB >> 19027048

Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older.

Alicia N Stein1, Helena Britt, Christopher Harrison, E Lynne Conway, Anthony Cunningham, C Raina Macintyre.   

Abstract

Incidence of zoster and post-herpetic neuralgia (PHN) and associated health care resource utilisation were investigated in the Australian population aged > or =50 years, using general practice data from 2000 to 2006, and pharmaceutical prescribing, hospital morbidity and emergency department data from 1998 to 2005. Zoster and PHN incidence rates were estimated as approximately 10/1000 and 1.45/1000 persons, respectively, with antivirals prescribed for 73.5% of zoster cases. Estimated hospitalisation and emergency department visit rates were 0.67/1000 and 0.38/1000 persons, respectively. Management of zoster (including PHN) involved approximately 2.4 general practitioner consultations. Total costs to the health care system were estimated as approximately 32.8 million per year. The substantial burden of zoster and PHN highlights the potential benefit of zoster vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027048     DOI: 10.1016/j.vaccine.2008.11.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

Review 2.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

Review 3.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Authors:  Ian H Frazer; Myron J Levin
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

Review 5.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

Review 6.  Vaccination for quality of life: herpes-zoster vaccines.

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Aging Clin Exp Res       Date:  2019-10-23       Impact factor: 3.636

7.  Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.

Authors:  Mona Marin; Barbara P Yawn; Craig M Hales; Peter C Wollan; Stephanie R Bialek; John Zhang; Marge J Kurland; Rafael Harpaz
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

9.  Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.

Authors:  Leonardo Emberti Gialloreti; Monica Merito; Patrizio Pezzotti; Luigi Naldi; Antonio Gatti; Maud Beillat; Laurence Serradell; Rafaelle di Marzo; Antonio Volpi
Journal:  BMC Infect Dis       Date:  2010-08-03       Impact factor: 3.090

10.  Herpes zoster eye complications: rates and trends.

Authors:  Barbara P Yawn; Peter C Wollan; Jennifer L St Sauver; Linda C Butterfield
Journal:  Mayo Clin Proc       Date:  2013-05-09       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.